Related references
Note: Only part of the references are listed.Final overall survival results of a randomized trial comparing bortezomib plus pegylated liposomal doxorubicin with bortezomib alone in patients with relapsed or refractory multiple myeloma
Robert Z. Orlowski et al.
CANCER (2016)
Same Data; Different Interpretations
Bishal Gyawali et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study
Meletios Dimopoulos et al.
LANCET ONCOLOGY (2013)
A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma
Jeffrey A. Zonder et al.
BLOOD (2012)
Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma
Jeffrey L. Wolf et al.
LEUKEMIA & LYMPHOMA (2012)
Addition of Bevacizumab to Chemotherapy for Treatment of Solid Tumors: Similar Results but Different Conclusions
Alberto Ocana et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens
K. L. Blackwell et al.
ANNALS OF ONCOLOGY (2009)
Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: An intergroup trial (E1193)
GW Sledge et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)